Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
6(55%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
2
18%
Ph not_applicable
4
36%
Ph phase_1
1
9%
Ph phase_2
4
36%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
2(18.2%)
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
4(36.4%)
N/ANon-phased studies
4(36.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

6

trials recruiting

Total Trials

11

all time

Status Distribution
Active(6)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Recruiting6
Completed2
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
6
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (18.2%)
Phase 11 (9.1%)
Phase 24 (36.4%)
N/A4 (36.4%)

Trials by Status

completed218%
unknown218%
withdrawn19%
recruiting655%

Recent Activity

6 active trials
Showing 5 of 11
recruitingnot_applicable

68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases

NCT06275477
completedphase_2

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

NCT05262855
withdrawnearly_phase_1

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

NCT06922825
completedphase_2

[68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer

NCT05898854
recruitingearly_phase_1

FAPI PET for Lung Fibrosis

NCT05365802
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06275477Not Applicable

68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases

Recruiting
NCT05262855Phase 2

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

Completed
NCT06922825Early Phase 1

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

Withdrawn
NCT05898854Phase 2

[68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer

Completed
NCT05365802Early Phase 1

FAPI PET for Lung Fibrosis

Recruiting
NCT05903807Phase 2

[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer

Recruiting
NCT06604260Phase 2

FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients

Recruiting
NCT06232122Not Applicable

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer

Recruiting
NCT05617742Not Applicable

Comparison of 68Ga-FAPI-46 PET and 18F-FDG PET in Lung Cancer

Unknown
NCT05263700Not Applicable

FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary

Unknown
NCT05172310Phase 1

PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

Recruiting

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11